These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 1672042

  • 1. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
    Lee MT, Liebow C, Kamer AR, Schally AV.
    Proc Natl Acad Sci U S A; 1991 Mar 01; 88(5):1656-60. PubMed ID: 1672042
    [Abstract] [Full Text] [Related]

  • 2. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV.
    Pancreas; 1993 Jan 01; 8(1):88-97. PubMed ID: 8093555
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Jan 01; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 4. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
    Liebow C, Lee MT, Kamer AR, Schally AV.
    Proc Natl Acad Sci U S A; 1991 Mar 15; 88(6):2244-8. PubMed ID: 1672452
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct 15; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 6. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
    Lee LT, Schally AV, Liebow C, Lee PP, Lee PH, Lee MT.
    Anticancer Res; 2008 Oct 15; 28(5A):2599-605. PubMed ID: 19035284
    [Abstract] [Full Text] [Related]

  • 7. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M, Zalatnai A, Schally AV.
    Cancer Lett; 1989 May 15; 45(2):87-91. PubMed ID: 2567204
    [Abstract] [Full Text] [Related]

  • 8. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV.
    Pancreas; 1989 May 15; 4(5):521-8. PubMed ID: 2573055
    [Abstract] [Full Text] [Related]

  • 9. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec 15; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1061-7. PubMed ID: 1981009
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
    Liebow C, Reilly C, Serrano M, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 20; 86(6):2003-7. PubMed ID: 2564678
    [Abstract] [Full Text] [Related]

  • 12. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
    Paz-Bouza JI, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1987 Feb 20; 84(4):1112-6. PubMed ID: 2881296
    [Abstract] [Full Text] [Related]

  • 13. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
    Fekete M, Wittliff JL, Schally AV.
    J Clin Lab Anal; 1989 Feb 20; 3(3):137-47. PubMed ID: 2569034
    [Abstract] [Full Text] [Related]

  • 14. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis.
    Crean DH, Liebow C, Lee MT, Kamer AR, Schally AV, Mang TS.
    J Cancer Res Clin Oncol; 1995 Feb 20; 121(3):141-9. PubMed ID: 7713985
    [Abstract] [Full Text] [Related]

  • 15. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B, Zalatnai A, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 20; 86(5):1643-7. PubMed ID: 2564204
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
    Szende B, Srkalovic G, Schally AV, Lapis K, Groot K.
    Cancer; 1990 May 15; 65(10):2279-90. PubMed ID: 1971771
    [Abstract] [Full Text] [Related]

  • 17. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T, Redding TW, Ben-David M, Schally AV.
    Proc Natl Acad Sci U S A; 1988 Feb 15; 85(3):890-4. PubMed ID: 2893378
    [Abstract] [Full Text] [Related]

  • 18. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A, Schally AV.
    Cancer Res; 1989 Apr 01; 49(7):1810-5. PubMed ID: 2564312
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1985 Feb 01; 82(4):1252-6. PubMed ID: 2858096
    [Abstract] [Full Text] [Related]

  • 20. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.